Management of Atrial Fibrillation with Heart Failure and Hyperthyroidism

Immediate Rate Control Strategy

The American College of Cardiology recommends beta-blockers as the first-line therapy for rate control in patients with atrial fibrillation, heart failure, and hyperthyroidism, with immediate initiation to address both the cardiac arrhythmia and the thyrotoxic state 1, 2, 3
Beta-blockers control ventricular rate in AF with rapid ventricular response, and inhibit peripheral conversion of T4 to T3, directly addressing the thyrotoxic state 1, 4
The American College of Cardiology provides a Class I recommendation for hyperthyroidism-related AF, indicating that beta-blockers are the preferred treatment 1, 2, 3
In the acute setting with rapid ventricular response, IV beta-blockers (esmolol, metoprolol, or propranolol) should be administered immediately, exercising caution in patients with overt congestion or hypotension 1, 4
High doses of beta-blockers may be required in severe thyrotoxicosis or thyroid storm 2, 3

The European Heart Journal recommends initiating or continuing oral anticoagulation based on CHA₂DS₂-VASc score, not thyroid status, with a target INR 2.0-3.0 with warfarin, or using direct oral anticoagulants 2, 3
Anticoagulation decisions are identical to non-thyrotoxic AF, and age alone (≥65 years) or heart failure gives CHA₂DS₂-VASc score ≥2, mandating anticoagulation 5

The European Heart Journal recommends not attempting cardioversion or using antiarrhythmic drugs until euthyroid state is achieved, as cardioversion and antiarrhythmic drugs are generally unsuccessful while thyrotoxicosis persists 2, 3, 6
Defer attempted cardioversion until approximately 4 months after maintaining euthyroid state, and normalizing thyroid function prior to cardioversion reduces relapse risk 7

The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel antagonists for rate control in patients with heart failure with preserved ejection fraction (HFpEF) 1
For patients with heart failure with reduced ejection fraction (HFrEF), beta-blockers remain first-line despite HFrEF, but use caution with overt congestion or hypotension, and combination therapy with digoxin and beta-blocker is reasonable to control resting and exercise heart rate 1, 4

The American College of Cardiology warns against using digoxin as monotherapy for acute rate control in thyrotoxic AF, as it is less effective in hyperthyroid states 5, 6
The European Heart Journal warns against using amiodarone in patients with active hyperthyroidism due to risk of fatal thyroid storm 7
The American College of Cardiology warns against withholding anticoagulation based solely on hyperthyroidism, and recommends using CHA₂DS₂-VASc score to determine anticoagulation needs 5